Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-13905
Oberholzer, P A; Urosevic, M; Steinert, H C; Dummer, R (2008). Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography. Dermatology, 217(4):351-355.
|PDF - Registered users only|
BACKGROUND: Baseline staging is important in all melanoma types, including melanoma with unknown primary site (MUP). Staging includes different examination strategies, each with different accuracy. OBJECTIVE: To determine the value of serum S100 protein levels and positron emission tomography (PET) in the baseline staging of MUP. METHODS: Twenty patients with MUP were evaluable for the analysis between 1996 and 2007 with both S100 assessment and PET performed for baseline staging. RESULTS: Serum S100 was elevated in 7 patients (35%). The PET scan detected the metastases in 6 of 7 patients with elevated serum S100 protein showing a strong correlation (p = 0.005). Patients with metastases had significantly higher serum S100 levels (p = 0.01) than the ones without. Serum S100 protein was shown to be discriminative between patients with and without metastases (receiver-operating characteristic, p = 0.012) with 75% sensitivity and 92% specificity. CONCLUSION: Serum S100 protein appears to be a sensitive as well as specific marker to detect metastases. We therefore might recommend serum S100 assessment to be included in the baseline staging of MUP.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||26 Feb 2009 16:11|
|Last Modified:||27 Nov 2013 19:21|
|Citations:||Web of Science®. Times Cited: 5|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page